Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | ($159.2K) | ($3,427.8K) | ($11.0M) | ($40.3M) | ($58.4M) | ($13.7M) | ($11.4M) | ($6,775.6K) | ($10.6M) | ($15.8M) | ($28.0M) | ($37.0M) | ($35.7M) | ($13.1M) | $13.1M | ($30.5M) | ($52.7M) | ($86.1M) | ($74.4M) | ($614.9M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Summit Therapeutics Inc.'s last 12-month Net Income is ($196.7M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Summit Therapeutics Inc.'s Net Income growth was (88.0%). The average annual Net Income growth rates for Summit Therapeutics Inc. have been 45.4% over the past three years, 41.4% over the past five years.
Over the last year, Summit Therapeutics Inc.'s Net Income growth was (88.0%), which is lower than industry growth of (0.1%). It indicates that Summit Therapeutics Inc.'s Net Income growth is Bad.